Immune reactivity modifications related to uptake of Adriamycin by hematopoietic cells (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Immune reactivity modifications related to uptake of Adriamycin by hematopoietic cells (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A2709 1993. Unique Identifier : AIDSLINE MED/93693653
Zaleskis G; Ehrke MJ; Maccubbin D; Ujhazy P; Eppolito C; Mihich E; Grace Cancer Drug Center, Roswell Park Cancer Inst., Buffalo, NY 14263

Abstract: The purpose of this study was to evaluate the relationship between Adriamycin (ADM) uptake by murine spleen and thymus cells and cellular immune parameters after a single low-dose (5 mg/kg iv) ADM injection. ADM treatment resulted in reduced thymic cellularity; the most sensitive cells being CD3(lo)4+8+ T cells decreased 2- to 3-fold), whereas CD3(hi)4-8- and mature single positive CD4+/8+ subsets were relatively resistant. Spleen cellularity was moderately decreased by ADM due to a decrease in non-T cells. The proliferative response to IL2 of spleen or thymus cells from drug-treated mice was reduced relative to control cells up to 3 days after treatment. In spite of this, the cytolytic activity generated with spleen cells harvested 5 or 12 days after ADM was elevated relative to control. As determined by flow cytometry, drug accumulation in both spleen and thymus cells was max 1 day after injection and ADM was still detectable on day 5 but not day 12. When exposed to ADM in vitro, drug was found in all cell subsets, but was concentrated in the cytoplasm of macrophages and the nucleus of lymphocytes.
Keywords: *Doxorubicin/PHARMACOKINETICS *Spleen/METABOLISM *Thymus Gland/METABOLISMKWDdoxorubicin/pharmacokineticsKWDspleen/metabolismKWDthymusgland/metabolism
931130
M93B5839

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .